step 1 trial semaglutide 2.4 mg weight loss nejm 2021 Phase 3 of in Metabolic Dysfunction–Associated Steatohepatitis Semaglutide 2.4-mg Injection as a
Description
This gradual titration helps reduce gastrointestinal side effects such as nausea, diarrhea, and constipation
People with this condition fall asleep at unwelcome times, including when driving or giving a presentation
Individual tolerance varies based on genetic factors, baseline gastrointestinal sensitivity, and dose escalation speed
Nothing in the published data licenses treating this molecule as a finished, approved medicine
These insights highlight the importance of comprehensive, long-term strategies in obesity management
